We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Curis (CRIS) Skyrockets on Promising Phase I Pipeline Updates
Read MoreHide Full Article
Curis, Inc. (CRIS - Free Report) announced promising preliminary data from two early-stage studies evaluating its pipeline candidate, CA-4948, in hematologic malignancies on two consecutive days, which pushed its stock more than 350% higher on Dec 8.
The company is evaluating a monotherapy of CA-4948, an IRAK4 kinase inhibitor, in a phase I study in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). Another phase I study is evaluating the candidate in patients with relapsed or refractory (R/R) non-Hodgkin's lymphoma (NHL), including patients with diffuse large B-cell lymphoma (DLBCL), Waldenström's macroglobulinemia (WM) and oncogenic MYD88 mutations.
On Dec 8, the company announced that all evaluable patients receiving 200 mg twice daily (BID) dose of CA-4948 in the AML/MDS study achieved marrow blast reductions with one-third of them achieving a marrow complete response. No dose-limiting toxicities were observed in the study. The company started enrolment in the 400 mg BID cohort of the study.
On Dec 7, Curis had announced preliminary data from the NHL study, evaluating seven different dosage regimens of CA-4948. The data demonstrated durable anti-cancer activity of single-agent CA-4948 therapy. The candidate achieved a mean reduction of 27% in tumor burden in six of seven evaluable patients. The candidate was also well-tolerated in patients. The company also announced 300mg BID dose of the candidate as the recommended dose for phase II study in NHL patients.
Shares of Curis were up 354.9% on Dec 8 as investors cheered the encouraging pipeline progress. The company’s shares have surged 285.3% so far this year compared with the industry’s rise of 5.8%.
Apart from CA-4948 monotherapy, the company plans to initiate a phase I study to evaluate the candidate in combination with J&J (JNJ - Free Report) /AbbVie’s (ABBV - Free Report) Imbruvica (ibrutinib) in NHL patients soon.
Apart from hematologic malignancies, the company is also developing one immune checkpoint inhibitor, CI-8993, as antagonist to VISTA signaling pathway for cancer patients. The company plans to initiate a clinical study on the candidate by year-end.
The company also has one marketed drug in its portfolio, Erivedge, which is approved as a treatment for advanced basal cell carcinoma, a type of skin cancer. The company has a collaboration with Roche (RHHBY - Free Report) related to commercialization of the drug.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Image: Bigstock
Curis (CRIS) Skyrockets on Promising Phase I Pipeline Updates
Curis, Inc. (CRIS - Free Report) announced promising preliminary data from two early-stage studies evaluating its pipeline candidate, CA-4948, in hematologic malignancies on two consecutive days, which pushed its stock more than 350% higher on Dec 8.
The company is evaluating a monotherapy of CA-4948, an IRAK4 kinase inhibitor, in a phase I study in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). Another phase I study is evaluating the candidate in patients with relapsed or refractory (R/R) non-Hodgkin's lymphoma (NHL), including patients with diffuse large B-cell lymphoma (DLBCL), Waldenström's macroglobulinemia (WM) and oncogenic MYD88 mutations.
On Dec 8, the company announced that all evaluable patients receiving 200 mg twice daily (BID) dose of CA-4948 in the AML/MDS study achieved marrow blast reductions with one-third of them achieving a marrow complete response. No dose-limiting toxicities were observed in the study. The company started enrolment in the 400 mg BID cohort of the study.
On Dec 7, Curis had announced preliminary data from the NHL study, evaluating seven different dosage regimens of CA-4948. The data demonstrated durable anti-cancer activity of single-agent CA-4948 therapy. The candidate achieved a mean reduction of 27% in tumor burden in six of seven evaluable patients. The candidate was also well-tolerated in patients. The company also announced 300mg BID dose of the candidate as the recommended dose for phase II study in NHL patients.
Shares of Curis were up 354.9% on Dec 8 as investors cheered the encouraging pipeline progress. The company’s shares have surged 285.3% so far this year compared with the industry’s rise of 5.8%.
Apart from CA-4948 monotherapy, the company plans to initiate a phase I study to evaluate the candidate in combination with J&J (JNJ - Free Report) /AbbVie’s (ABBV - Free Report) Imbruvica (ibrutinib) in NHL patients soon.
Apart from hematologic malignancies, the company is also developing one immune checkpoint inhibitor, CI-8993, as antagonist to VISTA signaling pathway for cancer patients. The company plans to initiate a clinical study on the candidate by year-end.
The company also has one marketed drug in its portfolio, Erivedge, which is approved as a treatment for advanced basal cell carcinoma, a type of skin cancer. The company has a collaboration with Roche (RHHBY - Free Report) related to commercialization of the drug.
Curis, Inc. Price
Curis, Inc. price | Curis, Inc. Quote
Zacks Rank
Curis currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>